Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting....

Full description

Saved in:

Bibliographic Details
Published in:	Drug design, development and therapy Vol. 11; pp. 2399 - 2408
Main Authors:	Ríos-Tamayo, Rafael, Martín-García, Agustín, Alarcón-Payer, Carolina, Sánchez-Rodríguez, Dolores, de la Guardia, Ana María Del Valle Díaz, García Collado, Carlos Gustavo, Jiménez Morales, Alberto, Jurado Chacón, Manuel, Cabeza Barrera, José
Format:	Journal Article
Language:	English
Published:	New Zealand Dove Medical Press Limited 01-01-2017 Taylor & Francis Ltd Dove Medical Press
Subjects:	Analysis Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Care and treatment Clinical trials Cytogenetics Dexamethasone Dexamethasone - administration & dosage Disease Dosage and administration Drug Design Drug dosages Drug therapy Evidence-based medicine Humans Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Immunomodulation Medical prognosis Multiple Myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Patients Pharmacology Pomalidomide Proteins Renal failure Review Steroids Survival Rate Thalidomide - administration & dosage Thalidomide - adverse effects Thalidomide - analogs & derivatives Thalidomide - therapeutic use Working groups Spain dexamethasone multiple myeloma triplet therapy pomalidomide
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.
ISSN:	1177-8881 1177-8881
DOI:	10.2147/DDDT.S115456